TN2016000196A1 - Utilisation d'antagonistes par-1 pour la prevention et/ou le traitement des pathologies fonctionnelles pelvi-perineales. - Google Patents
Utilisation d'antagonistes par-1 pour la prevention et/ou le traitement des pathologies fonctionnelles pelvi-perineales.Info
- Publication number
- TN2016000196A1 TN2016000196A1 TN2016000196A TN2016000196A TN2016000196A1 TN 2016000196 A1 TN2016000196 A1 TN 2016000196A1 TN 2016000196 A TN2016000196 A TN 2016000196A TN 2016000196 A TN2016000196 A TN 2016000196A TN 2016000196 A1 TN2016000196 A1 TN 2016000196A1
- Authority
- TN
- Tunisia
- Prior art keywords
- prevention
- treatment
- antagonists
- pelvi
- par
- Prior art date
Links
- 229940098892 Protease-activated receptor-1 antagonist Drugs 0.000 title abstract 2
- 230000002265 prevention Effects 0.000 title abstract 2
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 abstract 1
- QWKAUGRRIXBIPO-UHFFFAOYSA-N Atopaxar Chemical compound N=C1C=2C(F)=C(OCC)C(OCC)=CC=2CN1CC(=O)C(C=C(C=1OC)C(C)(C)C)=CC=1N1CCOCC1 QWKAUGRRIXBIPO-UHFFFAOYSA-N 0.000 abstract 1
- 206010011796 Cystitis interstitial Diseases 0.000 abstract 1
- 208000005615 Interstitial Cystitis Diseases 0.000 abstract 1
- 229950007648 atopaxar Drugs 0.000 abstract 1
- 230000007170 pathology Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229960005044 vorapaxar Drugs 0.000 abstract 1
- ZBGXUVOIWDMMJE-QHNZEKIYSA-N vorapaxar Chemical compound C(/[C@@H]1[C@H]2[C@H](C(O[C@@H]2C)=O)C[C@H]2[C@H]1CC[C@H](C2)NC(=O)OCC)=C\C(N=C1)=CC=C1C1=CC=CC(F)=C1 ZBGXUVOIWDMMJE-QHNZEKIYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1362682A FR3014693B1 (fr) | 2013-12-16 | 2013-12-16 | Utilisation de la 3-(2-chloro-phenyl)-1-[4-(4-fluoro-benzyl)-piperazin-1-yl]-propenone pour la prevention et/ou le traitement des pathologies fonctionnelles pelvi-perineales |
| PCT/EP2014/073453 WO2015090705A1 (fr) | 2013-12-16 | 2014-10-31 | Utilisation d'antagonistes par-1 pour la prevention et/ou le traitement des pathologies fonctionnelles pelvi-perineales |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TN2016000196A1 true TN2016000196A1 (fr) | 2017-10-06 |
Family
ID=50424483
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TN2016000196A TN2016000196A1 (fr) | 2013-12-16 | 2014-10-31 | Utilisation d'antagonistes par-1 pour la prevention et/ou le traitement des pathologies fonctionnelles pelvi-perineales. |
Country Status (16)
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR3090317B1 (fr) * | 2018-12-19 | 2021-05-07 | Cvasthera | Utilisation d’un antagoniste de par-1 pour le traitement d’une maladie inflammatoire chronique intestinale |
| CN110393718B (zh) * | 2019-08-20 | 2022-10-04 | 青岛海洋生物医药研究院 | 阿托帕沙溴酸作为新型jak-stat3信号通路抑制剂的用途和研究方法 |
| FR3109089B1 (fr) * | 2020-04-08 | 2023-04-14 | Cvasthera | Composition pharmaceutique pour le traitement des maladies inflammatoires intestinales |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1982984B1 (en) | 2002-04-16 | 2013-02-13 | Merck Sharp & Dohme Corp. | Manufacture of tricyclic thrombin receptor antagonists and pharmaceutical compositions comprising them |
| US8440627B2 (en) * | 2004-11-04 | 2013-05-14 | Tufts Medical Center, Inc. | G protein coupled receptor agonists and antagonists and methods of use |
| FR2902426B1 (fr) * | 2006-06-19 | 2008-09-05 | Pierre Fabre Medicament Sa | Derives de cinnamoyl-piperazine |
| CA2834621A1 (en) * | 2011-05-12 | 2012-11-15 | Universite Laval | Par1 inhibitors for use in the treatment or prevention of paramyxoviridae infections |
| RU2468759C1 (ru) * | 2011-09-23 | 2012-12-10 | Ольга Викторовна Тарабанова | Способ лечения нарушений анатомических соотношений органов малого таза у женщин с атрофией мышц, поднимающих задний проход, и/или множественными дефектами ректо-вагинальной фасции |
-
2013
- 2013-12-16 FR FR1362682A patent/FR3014693B1/fr not_active Expired - Fee Related
-
2014
- 2014-10-31 US US15/101,170 patent/US9980970B2/en not_active Expired - Fee Related
- 2014-10-31 CN CN201480068095.9A patent/CN105813642B/zh not_active Expired - Fee Related
- 2014-10-31 MX MX2016007795A patent/MX370061B/es active IP Right Grant
- 2014-10-31 WO PCT/EP2014/073453 patent/WO2015090705A1/fr not_active Ceased
- 2014-10-31 JP JP2016540042A patent/JP6612233B2/ja not_active Expired - Fee Related
- 2014-10-31 AU AU2014365665A patent/AU2014365665B2/en not_active Ceased
- 2014-10-31 RU RU2016127158A patent/RU2678309C1/ru not_active IP Right Cessation
- 2014-10-31 KR KR1020167017262A patent/KR20160089518A/ko not_active Ceased
- 2014-10-31 UA UAA201607312A patent/UA120603C2/uk unknown
- 2014-10-31 CA CA2931161A patent/CA2931161A1/fr not_active Abandoned
- 2014-10-31 EP EP14793086.1A patent/EP3082818A1/fr not_active Withdrawn
- 2014-10-31 MA MA39072A patent/MA39072A1/fr unknown
- 2014-10-31 TN TN2016000196A patent/TN2016000196A1/fr unknown
-
2016
- 2016-06-14 IL IL246216A patent/IL246216A0/en unknown
- 2016-06-16 SA SA516371348A patent/SA516371348B1/ar unknown
-
2018
- 2018-04-25 US US15/962,837 patent/US10265322B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN105813642B (zh) | 2019-05-03 |
| MA39072A1 (fr) | 2017-05-31 |
| EP3082818A1 (fr) | 2016-10-26 |
| UA120603C2 (uk) | 2020-01-10 |
| US9980970B2 (en) | 2018-05-29 |
| MX2016007795A (es) | 2016-09-07 |
| US20180311253A1 (en) | 2018-11-01 |
| AU2014365665B2 (en) | 2019-08-29 |
| US20160287603A1 (en) | 2016-10-06 |
| KR20160089518A (ko) | 2016-07-27 |
| JP6612233B2 (ja) | 2019-11-27 |
| FR3014693B1 (fr) | 2016-01-08 |
| RU2678309C1 (ru) | 2019-01-25 |
| AU2014365665A1 (en) | 2016-07-14 |
| IL246216A0 (en) | 2016-07-31 |
| SA516371348B1 (ar) | 2019-11-10 |
| US10265322B2 (en) | 2019-04-23 |
| WO2015090705A1 (fr) | 2015-06-25 |
| FR3014693A1 (fr) | 2015-06-19 |
| MX370061B (es) | 2019-11-29 |
| JP2016540799A (ja) | 2016-12-28 |
| CA2931161A1 (fr) | 2015-06-25 |
| CN105813642A (zh) | 2016-07-27 |
| HK1221913A1 (zh) | 2017-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA67726B1 (fr) | Utilisations thérapeutiques de dérivés deutérés du lanifibranor | |
| CY1122266T1 (el) | Ενωσεις 3-αμινοκυκλοαλκυλιου ως ror-gamma-t αναστολεις και χρησεις αυτων | |
| MX2015010921A (es) | Compuestos de carbazol utiles como inhibidores de bromodominio. | |
| MX2015008957A (es) | Fluoro-[1,3]oxazinas como inhibidores de beta-secretasa 1 (bace1). | |
| EA201590457A1 (ru) | Сульфамоил-ариламиды и их применение в качестве лекарственных препаратов для лечения гепатита b | |
| MX2015017964A (es) | Inhibidores de bromodominio. | |
| MA42410A (fr) | Oxystérols et leurs méthodes d'utilisation | |
| TR201904455T4 (tr) | Nükleer taşıma modülatörleri olarak 1,2,4-triazoller ve bunların kullanımları. | |
| EA201390803A1 (ru) | Ингибиторы бромодомена и их применение | |
| EA201492290A1 (ru) | Составы и способы для вагинальной доставки антипрогестинов | |
| EA201690872A3 (ru) | Противовирусная терапия | |
| MA38253B1 (fr) | Compositions comprenant de la vortioxétine et du donépézil | |
| EA201290860A1 (ru) | Лечение ревматоидного артрита комбинацией лаквинимода и метотрексата | |
| MA38810A1 (fr) | Inhibiteurs de rorc2 méthodes d'utilisation associées | |
| EA201290859A1 (ru) | Лечение люпус-артрита с использованием лаквинимода | |
| ECSP13012573A (es) | 6-amino-nicotinamidas sustituidas como moduladores de KCNQ2/3 | |
| EA201990424A1 (ru) | Спиролактамовые модуляторы nmda-рецептора и их применение | |
| MY174747A (en) | Bace1 inhibitors | |
| JO3676B1 (ar) | مركبات صيدلانية تضم فوكانات معدلة وطرق تتعلق بها | |
| CR20110267A (es) | Tratamiento de transtornos cognitivos con (r)-7-cloro-n-(quinuclidin-3-il) benzo[]tiofeno-2-carboxamida y sales farmacéuticamente aceptables de la misma | |
| MX2016002580A (es) | Combinacion de un inhibidor de alk y un inhibidor de cdk para el tratamiento de enfermedades celulares proliferativas. | |
| EA201500575A1 (ru) | Транс-4-{2-[4-(2,3-дихлорфенил)пиперазин-1-ил]этил}-n,n-диметилкарбамоилциклогексиламин для лечения негативных симптомов шизофрении | |
| EA201791009A1 (ru) | Композиции, содержащие циклоспорин | |
| MX377733B (es) | Tratamiento de enfermedad de alzheimer leve y moderada. | |
| MA39072A1 (fr) | Utilisation d'antagonistes par-1 pour la prevention et/ou le traitement des pathologies fonctionnelles pelvi-perineales |